Drawing for NEO-ANGIN

USPTO serial 79000929

NEO-ANGIN

Reviewed by CopyMark Law Group

Reg. 3041836Status 404
Filing date
Status date
Registration date
Jan 10, 2006
Examiner
SHEFFIELD, SHARI
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with NEO-ANGIN?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Julie B Seyler

JULIE B SEYLER ABELMAN, FRAYNE & SCHWAB150 E 42ND STNEW YORK, NY 10017-5612UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical products, namely proprietary medicines against the common cold, influenza and sore throat; cough drops, lozenges, sweets for the throatSECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 18, 2019UNDNUNDELIVERABLE MAIL - NO ACTION TAKEN—
Nov 1, 2019DENCNOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED—
Nov 1, 2019DETHDEATH OF INTERNATIONAL REGISTRATION—
Dec 7, 2018NREPNEW REPRESENTATIVE AT IB RECEIVED—
Mar 23, 2018NREPNEW REPRESENTATIVE AT IB RECEIVED—
May 22, 2014INNTTOTAL INVALIDATION PROCESSED BY THE IB—
May 8, 2014NREPNEW REPRESENTATIVE AT IB RECEIVED—
Mar 31, 2014INTSTOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
Apr 17, 2013INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED—
Aug 17, 2012C71TCANCELLED SECTION 71—
Apr 23, 2009RNWLINTERNATIONAL REGISTRATION RENEWED—
Sep 7, 2006FINVFINAL DECISION TRANSACTION PROCESSED BY IB—
Sep 7, 2006FINVFINAL DECISION TRANSACTION PROCESSED BY IB—
Aug 18, 2006FICSFINAL DISPOSITION NOTICE SENT TO IB—
Aug 17, 2006FIMPFINAL DISPOSITION PROCESSED—
Aug 10, 2006FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Jan 10, 2006R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Oct 18, 2005PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 28, 2005NPUBNOTICE OF PUBLICATION—
Aug 18, 2005OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Aug 4, 2005OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Aug 4, 2005OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Jul 7, 2005PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Jul 1, 2005ALIEASSIGNED TO LIE—
Jun 24, 2005CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Dec 28, 2004ACECAMENDMENT FROM APPLICANT ENTERED—
Dec 13, 2004UNPRUNRESPONSIVE/DUPLICATE PAPER RECEIVED—
Dec 13, 2004MAILPAPER RECEIVED—
Dec 13, 2004ACECAMENDMENT FROM APPLICANT ENTERED—
Dec 3, 2004CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 3, 2004MAILPAPER RECEIVED—
Oct 7, 2004RFNTREFUSAL PROCESSED BY IB—
Sep 8, 2004CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 8, 2004DOCKASSIGNED TO EXAMINER—
Mar 11, 2004NWAPNEW APPLICATION ENTERED—
Mar 8, 2004SDRCSN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB—

Frequently asked questions

Related guidance